Tango Therapeutics Inc TNGX
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2020-09-03 |
| Shares Out. | 162,330,000 |
| Website | tangotx.com/ ↗ |
| Phone | 13026365400 |
| Employees | 137 |
| Net Income | -$45.5M |
| Free Cash Flow | -$142.5M |
| Total Assets | $435.8M |
| Total Liabilities | $44.3M |
| Equity | $391.5M |
About Tango Therapeutics Inc
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.
Tango Therapeutics Inc is a publicly traded company under the ticker symbol TNGX on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
18 analysts (2026-07-01)